Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05988463 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
A Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Joseph C. Wu.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05988463: Recruiting Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Joseph C. Wu.
NCT05988463 is a Phase 1 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Joseph C. Wu. The registered enrollment target is 15 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05988463, a Phase 1 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Joseph C. Wu.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring . This will be a single-center randomized, double-blinded, placebo-controlled study of 20 weeks including up to 4 weeks for screening, followed by 12 weeks of oral artesunate treatment across 3 dose levels (dose escalation every 4 weeks), and 4 weeks of a washout (follow-up) period in participants with Idiopathic Pulmonary Fibrosis (IPF). The primary objective of the study is to evaluate the safety and tolerability of artesunate at 3 dose levels, and to select the dose(s) to carry forward into additional clinical testing. The secondary objective includes exploring the blood biomarkers present in participants with IPF at baseline and to investigate how those biomarkers change following artesunate treatment. The exploratory objectives include assessing the changes in the K-BILD and Leicester cough questionnaire scores and change in pulmonary function after artesunate administration.
Conditions Studied
Interventions
- DRUG Artesuante
- OTHER Placebo capsules
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2027-01-01 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 1 |
What NCT05988463 shows while recruiting
NCT05988463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Artesuante is the first listed.
NCT05988463 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05988463 about?
NCT05988463 is a clinical study titled "Dose-Escalation Study of Artesunate Patients With IPF". Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring . This will be a single-center randomized, double-blinded, placebo-controlled study of 20 weeks including u...
What is the current status of trial NCT05988463?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2027-01-01. Estimated completion is 2028-11-01.
What conditions does trial NCT05988463 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT05988463?
The interventions under investigation include: Artesuante (DRUG), Placebo capsules (OTHER).
Who is sponsoring clinical trial NCT05988463?
This trial is sponsored by Joseph C. Wu, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05988463 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05988463's enrollment target sits among peer trials
15 46th of 51 higher than 5 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ACTIVE NOT RECRUITING · Phase 1
-
Atezolizumab for Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI